CliffBio
small molecule

HEXALEN

ALTRETAMINE

Loss of exclusivity—loss of exclusivity
CompanyEisai →See this company's full patent-cliff portfolio

Drug detail

Brand nameHEXALEN
Active ingredientALTRETAMINE
Strength50MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalDecember 1990
Marketing statusDISCN

More from Eisai

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

HEXALEN patent cliff — loss of exclusivity — | CliffBio